For example, genes in pathways that have many targets, such as CTNNB1, STAT3, or RAF, genes downstream of pathways that may drive proliferation and have also many targets such as FOS or MYC or chromatin regulators such as EP300 or HDAC2 are potential targets that have been considered for cancer therapy [63,64,65]. This evidence concerns the gene MYC and cancer.